In a phase II clinical trial, Nguyen et al. enrolled 12 patients with metastatic melanoma and treated them with autologous TILs and low-dose subcutaneous IL-2 following non-myeloablative chemotherapy. This evidence concerns the gene IL2 and metastatic melanoma.